(Q39567268)

English

A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination

scientific article published on 17 August 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

A reversal in the vascularity of metastatic liver tumors from colorectal cancer after the cessation of chemotherapy plus bevacizumab: contrast-enhanced ultrasonography and histological examination (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Hiroshi Kitamura

1

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Shoichiro Koike

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Koh Nakazawa

3

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Hideyasu Matsumura

4

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kenta Yokoi

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Kan Nakagawa

6

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Masayuki Arai

7

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

publication date

17 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Journal of Surgical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

107

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

155-159

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Chemotherapy before liver resection of colorectal metastases: friend or foe?

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Sinusoidal obstruction syndrome and nodular regenerative hyperplasia are frequent oxaliplatin-associated liver lesions and partially prevented by bevacizumab in patients with hepatic colorectal metastasis

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Reversibility of capillary density after discontinuation of bevacizumab treatment

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Lack of Evidence for Increased Operative Morbidity After Hepatectomy with Perioperative Use of Bevacizumab: A Matched Case-Control Study

1 reference

https://api.crossref.org/works/10.1002%2FJSO.23244

21 January 2018

Identifiers

10.1002/JSO.23244

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39567268&oldid=1840969954"